Tadashi Honda

List of Publications by Year
in descending order

101 papers	5,528 citations	93792 39 h-index	93651 72 g-index
102 all docs	102 docs citations	102 times ranked	5102 citing authors

#	Article	IF	Citations
1	Pirin, an Nrf2-Regulated Protein, Is Overexpressed in Human Colorectal Tumors. Antioxidants, 2022, 11, 262.	2.2	8
2	Nrf2 activation reprograms macrophage intermediary metabolism and suppresses the type I interferon response. IScience, 2022, 25, 103827.	1.9	51
3	Inhibition of mitochondrial LonP1 protease by allosteric blockade of ATP binding and hydrolysis via CDDO and its derivatives. Journal of Biological Chemistry, 2022, 298, 101719.	1.6	6
4	The synthetic triterpenoids CDDO-TFEA and CDDO-Me, but not CDDO, promote nuclear exclusion of BACH1 impairing its activity. Redox Biology, 2022, 51, 102291.	3.9	12
5	Application of the inÂvivo oxidative stress reporter Hmox1 as mechanistic biomarker of arsenic toxicity. Environmental Pollution, 2021, 270, 116053.	3.7	12
6	Nrf2 activation does not affect adenoma development in a mouse model of colorectal cancer. Communications Biology, 2021, 4, 1081.	2.0	1
7	Downregulation of Keap1 Confers Features of a Fasted Metabolic State. IScience, 2020, 23, 101638.	1.9	21
8	Recent progress in the strategic incorporation of fluorine into medicinally active compounds. Journal of Fluorine Chemistry, 2019, 217, 29-40.	0.9	61
9	Design, Synthesis, and Biological Evaluations of Asymmetric Bow-Tie PAMAM Dendrimer-Based Conjugates for Tumor-Targeted Drug Delivery. ACS Omega, 2018, 3, 3717-3736.	1.6	29
10	Synthesis of a Next-Generation Taxoid by Rapid Methylation Amenable for ¹¹C-Labeling. Journal of Organic Chemistry, 2018, 83, 2847-2857.	1.7	9
11	Experimental Nonalcoholic Steatohepatitis and Liver Fibrosis AreÂAmeliorated by Pharmacologic Activation of Nrf2 (NF-E2 p45-Related Factor 2). Cellular and Molecular Gastroenterology and Hepatology, 2018, 5, 367-398.	2.3	154
12	Design and synthesis of tumor-targeting theranostic drug conjugates for SPECT and PET imaging studies. Bioorganic Chemistry, 2018, 76, 458-467.	2.0	8
13	Construction of Fused Tropone Systems Through Intramolecular Rh(I)-Catalyzed Carbonylative [2+2+2+1] Cycloadditon of Triynes. Frontiers in Chemistry, 2018, 6, 401.	1.8	3
14	C151 in KEAP1 is the main cysteine sensor for the cyanoenone class of NRF2 activators, irrespective of molecular size or shape. Scientific Reports, 2018, 8, 8037.	1.6	58
15	Synthesis of Colchicinoids and Allocolchicinoids through Rh(I)-Catalyzed [2+2+2+1] and [2+2+2] Cycloadditions of o-Phenylenetriynes with and without CO. Journal of Organic Chemistry, 2018, 83, 11623-11644.	1.7	14
16	Inâ€...Situ Observation of Thiol Michael Addition to a Reversible Covalent Drug in a Crystalline Sponge. Angewandte Chemie - International Edition, 2016, 55, 4919-4923.	7.2	59
17	Inâ€...Situ Observation of Thiol Michael Addition to a Reversible Covalent Drug in a Crystalline Sponge. Angewandte Chemie, 2016, 128, 5003-5007.	1.6	10
18	Electron affinity of tricyclic, bicyclic, and monocyclic compounds containing cyanoenones correlates with their potency as inducers of a cytoprotective enzyme. Bioorganic and Medicinal Chemistry Letters, 2016, 26, 4345-4349.	1.0	2

#	Article	IF	Citations
19	Aldo-keto reductases are biomarkers of NRF2 activity and are co-ordinately overexpressed in non-small cell lung cancer. British Journal of Cancer, 2016, 115, 1530-1539.	2.9	31
20	Antidepressant effects of TBE-31 and MCE-1, the novel Nrf2 activators, in an inflammation model of depression. European Journal of Pharmacology, 2016, 793, 21-27.	1.7	27
21	The acetylenic tricyclic bis(cyano enone), TBE-31, targets microtubule dynamics and cell polarity in migrating cells. Biochimica Et Biophysica Acta - Molecular Cell Research, 2016, 1863, 638-649.	1.9	5
22	New Monocyclic, Bicyclic, and Tricyclic Ethynylcyanodienones as Activators of the Keap1/Nrf2/ARE Pathway and Inhibitors of Inducible Nitric Oxide Synthase. Journal of Medicinal Chemistry, 2015, 58, 4738-4748.	2.9	26
23	Nrf2 Activation Protects against Solar-Simulated Ultraviolet Radiation in Mice and Humans. Cancer Prevention Research, 2015, 8, 475-486.	0.7	94
24	Targeting lipid peroxidation and mitochondrial imbalance in Friedreich's ataxia. Pharmacological Research, 2015, 99, 344-350.	3.1	64
25	Pharmacokinetics and pharmacodynamics of orally administered acetylenic tricyclic bis (cyanoenone), a highly potent Nrf2 activator with a reversible covalent mode of action. Biochemical and Biophysical Research Communications, 2015, 465, 402-407.	1.0	21
26	Synthesis of13C215N2-labeled anti-inflammatory and cytoprotective tricyclicbis(cyanoenone) ([13C215N2]-TBE-31) as an internal standard for quantification by stable isotope dilution LC-MS method. Journal of Labelled Compounds and Radiopharmaceuticals, 2014, 57, 606-610.	0.5	2
27	Chemical Tuning Enhances Both Potency Toward Nrf2 and In Vitro Therapeutic Index of Triterpenoids. Toxicological Sciences, 2014, 140, 462-469.	1.4	21
28	The Acetylenic Tricyclic Bis(cyano enone), TBE-31 Inhibits Nonâ€“Small Cell Lung Cancer Cell Migration through Direct Binding with Actin. Cancer Prevention Research, 2014, 7, 727-737.	0.7	14
29	Synthesis and biological evaluation of biotin conjugates of (Â±)-(4bS,8aR,10aS)-10a-ethynyl-4b,8,8-trimethyl-3,7-dioxo-3,4b,7,8,8a,9,10,10a-octahydro-phenanthrene-2,6-dicarbonitrile, an activator of the Keap1/Nrf2/ARE pathway, for the isolation of its protein targets. Bioorganic and Medicinal Chemistry Letters, 2013, 23, 5540-5543.	1.0	4
30	Microwave-assisted Dielsâ€“Alder reactions between Danishefsky's diene and derivatives of ethyl Î±-(hydroxymethyl)acrylate. Synthetic approach toward a biotinylated anti-inflammatory monocyclic cyanoenone. Tetrahedron, 2013, 69, 2052-2055.	1.0	8
31	An Improved Synthesis of a Hydroxymethyl Tricyclic Ketone from Cyclohexanone, the Key Processes for the Synthesis of a Highly Potent Anti-inflammatory and Cytoprotective Agent. Synthesis, 2013, 45, 3251-3254.	1.2	17
32	Highly Potent Activation of Nrf2 by Topical Tricyclic Bis(Cyano Enone): Implications for Protection against UV Radiation during Thiopurine Therapy. Cancer Prevention Research, 2012, 5, 973-981.	0.7	32
33	(Â±)-(4bS,8aR,10aS)-10a-Ethynyl-4b,8,8-trimethyl-3,7-dioxo-3,4b,7,8,8a,9,10,10a-octahydrophenanthrene-2,6-di Acta Crystallographica Section E: Structure Reports Online, 2012, 68, o3095-o3096.	0.2	0
34	Synthesis, Chemical Reactivity as Michael Acceptors, and Biological Potency of Monocyclic Cyanoenones, Novel and Highly Potent Anti-inflammatory and Cytoprotective Agents. Journal of Medicinal Chemistry, 2012, 55, 4837-4846.	2.9	53
35	Tricyclic Compounds Containing Nonenolizable Cyano Enones. A Novel Class of Highly Potent Anti-Inflammatory and Cytoprotective Agents. Journal of Medicinal Chemistry, 2011, 54, 1762-1778.	2.9	63
36	HSF1-Dependent Upregulation of Hsp70 by Sulfhydryl-Reactive Inducers of the KEAP1/NRF2/ARE Pathway. Chemistry and Biology, 2011, 18, 1355-1361.	6.2	96

#	Article	IF	Citations
37	Synthesis and biological evaluation of 1-[2-cyano-3,12-dioxooleana-1,9(11)-dien-28-oyl]-4-ethynylimidazole. A novel and highly potent anti-inflammatory and cytoprotective agent. Bioorganic and Medicinal Chemistry Letters, 2011, 21, 2188-2191.	1.0	18
38	2-Cyano-3,10-dioxooleana-1,9(11)-dien-28-oic acid anhydride. A novel and highly potent anti-inflammatory and cytoprotective agent. Bioorganic and Medicinal Chemistry Letters, 2010, 20, 2275-2278.	1.0	12
39	An Exceptionally Potent Inducer of Cytoprotective Enzymes. Journal of Biological Chemistry, 2010, 285, 33747-33755.	1.6	98
40	A dicyanotriterpenoid induces cytoprotective enzymes and reduces multiplicity of skin tumors in UV-irradiated mice. Biochemical and Biophysical Research Communications, 2008, 367, 859-865.	1.0	16
41	Prevention and Treatment of Experimental Estrogen Receptorâ€“Negative Mammary Carcinogenesis by the Synthetic Triterpenoid CDDO-Methyl Ester and the Rexinoid LG100268. Clinical Cancer Research, 2008, 14, 4556-4563.	3.2	65
42	The Synthetic Triterpenoid 2-Cyano-3,12-dioxooleana-1,9-dien-28-oic Acid-Imidazolide Alters Transforming Growth Factor Î²-dependent Signaling and Cell Migration by Affecting the Cytoskeleton and the Polarity Complex. Journal of Biological Chemistry, 2008, 283, 11700-11713.	1.6	29
43	The rexinoid LG100268 and the synthetic triterpenoid CDDO-methyl amide are more potent than erlotinib for prevention of mouse lung carcinogenesis. Molecular Cancer Therapeutics, 2008, 7, 1251-1257.	1.9	30
44	A Novel Acetylenic Tricyclic bis-(Cyano Enone) Potently Induces Phase 2 Cytoprotective Pathways and Blocks Liver Carcinogenesis Induced by Aflatoxin. Cancer Research, 2008, 68, 6727-6733.	0.4	49
45	Pharmacodynamic characterization of chemopreventive triterpenoids as exceptionally potent inducers of Nrf2-regulated genes. Molecular Cancer Therapeutics, 2007, 6, 154-162.	1.9	268
46	The Synthetic Triterpenoids CDDO-Methyl Ester and CDDO-Ethyl Amide Prevent Lung Cancer Induced by Vinyl Carbamate in A/J Mice. Cancer Research, 2007, 67, 2414-2419.	0.4	137
47	Novel Tricyclic Compounds Having Acetylene Groups at C-8a and Cyano Enones in Rings A and C:Â Highly Potent Anti-inflammatory and Cytoprotective Agents. Journal of Medicinal Chemistry, 2007, 50, 1731-1734.	2.9	27
48	Platforms and networks in triterpenoid pharmacology. Drug Development Research, 2007, 68, 174-182.	1.4	38
49	Novel semisynthetic analogues of betulinic acid with diverse cytoprotective, antiproliferative, and proapoptotic activities. Molecular Cancer Therapeutics, 2007, 6, 2113-2119.	1.9	55
50	The synthetic triterpenoid TP-222 inhibits RANKL stimulation of osteoclastogenesis and matrix metalloproteinase-9 expression. Journal of Rheumatology, 2007, 34, 1058-68.	1.0	4
51	Study on the Base-Catalyzed Reverse Vinylogous Aldol Reaction of (4aÎ²,5Î²)-4,4a,5,6,7,8-Hexahydro-5-hydroxy-1,4a-dimethylnaphthalen-2(3H)-one under Robinson Annulation Conditions. Journal of Organic Chemistry, 2006, 71, 416-419.	1.7	8
52	Synthesis of a Novel Dicyano Abietane Analogue:Â A Potential Antiinflammatory Agent. Journal of Organic Chemistry, 2006, 71, 3314-3316.	1.7	11
53	Design, synthesis, and anti-inflammatory activity both in vitro and in vivo of new betulinic acid analogues having an enone functionality in ring A. Bioorganic and Medicinal Chemistry Letters, 2006, 16, 6306-6309.	1.0	45
54	The synthetic triterpenoid 1-[2-cyano-3,12-dioxooleana-1,9(11)-dien-28-oyl]imidazole blocks nuclear factor-ÎºB activation through direct inhibition of IÎºB kinase Î². Molecular Cancer Therapeutics, 2006, 5, 3232-3239.	1.9	112

#	Article	IF	Citations
55	2-Cyano-3,12-dioxooleana-1,9(11)-diene-28-oic Acid Disrupts Microtubule Polymerization: A Possible Mechanism Contributing to Apoptosis. Molecular Pharmacology, 2006, 69, 1158-1165.	1.0	18
56	Potent Protection against Aflatoxin-Induced Tumorigenesis through Induction of Nrf2-Regulated Pathways by the Triterpenoid 1-[2-Cyano-3-,12-Dioxooleana-1,9(11)-Dien-28-Oyl]Imidazole. Cancer Research, 2006, 66, 2488-2494.	0.4	186
57	The Synthetic Triterpenoid CDDO-Imidazolide Suppresses STAT Phosphorylation and Induces Apoptosis in Myeloma and Lung Cancer Cells. Clinical Cancer Research, 2006, 12, 4288-4293.	3.2	110
58	Studies on the reactivity of CDDO, a promising new chemopreventive and chemotherapeutic agent: implications for a molecular mechanism of action. Bioorganic and Medicinal Chemistry Letters, 2005, 15, 2215-2219.	1.0	102
59	The Synthetic Triterpenoids, CDDO and CDDO-Imidazolide, Are Potent Inducers of Heme Oxygenase-1 and Nrf2/ARE Signaling. Cancer Research, 2005, 65, 4789-4798.	0.4	264
60	2-Cyano-3,12-dioxooleana-1,9-dien-28-imidazolide (CDDO-Im) Directly Targets Mitochondrial Glutathione to Induce Apoptosis in Pancreatic Cancer. Journal of Biological Chemistry, 2005, 280, 36273-36282.	1.6	100
61	Extremely potent triterpenoid inducers of the phase 2 response: Correlations of protection against oxidant and inflammatory stress. Proceedings of the National Academy of Sciences of the United States of America, 2005, 102, 4584-4589.	3.3	506
62	AN EFFICIENT SYNTHESIS OF TRICYCLIC COMPOUNDS, (Â±)-(4aÎ²,8aÎ²,10aÎ±)-1,2,3,4,4a,6,7,8,8a,9,10,10a-DODECAHYDRO-1,1,4a-TRIMETHYL-2-OXOPHENANTHRENE-8a-CARBOXYLIC ACID, ITS METHYL ESTER, AND (Â±)-(4aÎ²,8aÎ²,10aÎ±)-3,4,4a,6,7,8,8a,9,10,10a-DECAHYDRO-8a-HYDROXYMETHYL-1,1,4a-TRIMETHYLPHENANTHREN-2(1H)-ONE. Organic Preparations and Procedures International, 2005, 37, 546-550.	0.6	5
63	Design, Synthesis, and Biological Evaluation of Biotin Conjugates of 2-Cyano-3,12-dioxooleana-1,9(11)-dien-28-oic Acid for the Isolation of the Protein Targets. Journal of Medicinal Chemistry, 2004, 47, 4923-4932.	2.9	54
64	The bortezomib/proteasome inhibitor PS-341 and triterpenoid CDDO-Im induce synergistic antiâ€“multiple myeloma (MM) activity and overcome bortezomib resistance. Blood, 2004, 103, 3158-3166.	0.6	122
65	Revision and Confirmation of the Regiochemistry of Isoxazoles Derived from Methyl Oleanonate and Lanost-8-en-3-one. Synthesis of a New Lanostane Triterpenoid with a Cyano-enone Functionality in Ring A. Journal of Organic Chemistry, 2003, 68, 4991-4993.	1.7	12
66	Efficient synthesis of (â^')- and (+)-tricyclic compounds with enone functionalities in rings A and C. A novel class of orally active anti-inflammatory and cancer chemopreventive agents. Organic and Biomolecular Chemistry, 2003, 1, 4384-4391.	1.5	31
67	Synthetic triterpenoids enhance transforming growth factor beta/Smad signaling. Cancer Research, 2003, 63, 1371-6.	0.4	77
68	The novel synthetic triterpenoid, CDDO-imidazolide, inhibits inflammatory response and tumor growth in vivo. Clinical Cancer Research, 2003, 9, 2798-806.	3.2	120
69	The novel triterpenoid CDDO and its derivatives induce apoptosis by disruption of intracellular redox balance. Cancer Research, 2003, 63, 5551-8.	0.4	86
70	Partial Synthesis of 23-Hydroxyursolic Acid Isolated from Medicinal Plants of the Rubiaceae Family. Natural Product Research, 2002, 16, 273-276.	0.4	10
71	Novel triterpenoid CDDO-Me is a potent inducer of apoptosis and differentiation in acute myelogenous leukemia. Blood, 2002, 99, 326-335.	0.6	162
72	Design and Synthesis of Tricyclic Compounds with Enone Functionalities in Rings A and C:Â A Novel Class of Highly Active Inhibitors of Nitric Oxide Production in Mouse Macrophages. Journal of Medicinal Chemistry, 2002, 45, 4801-4805.	2.9	31

#	Article	IF	Citations
73	A novel dicyanotriterpenoid, 2-cyano-3,12-dioxooleana-1,9(11)-dien-28-onitrile, active at picomolar concentrations for inhibition of nitric oxide production. Bioorganic and Medicinal Chemistry Letters, 2002, 12, 1027-1030.	1.0	134
74	Identification of a novel synthetic triterpenoid, methyl-2-cyano-3,12-dioxooleana-1,9-dien-28-oate, that potently induces caspase-mediated apoptosis in human lung cancer cells. Molecular Cancer Therapeutics, 2002, 1, 177-84.	1.9	45
75	Synthetic Oleanane and Ursane Triterpenoids with Modified Rings A and C:â€‰ A Series of Highly Active Inhibitors of Nitric Oxide Production in Mouse Macrophages. Journal of Medicinal Chemistry, 2000, 43, 4233-4246.	2.9	217
76	Novel Synthetic Oleanane and Ursane Triterpenoids with Various Enone Functionalities in Ring A as Inhibitors of Nitric Oxide Production in Mouse Macrophagesâ€. Journal of Medicinal Chemistry, 2000, 43, 1866-1877.	2.9	113
77	Synthesis of Î²-Boswellic Acid Analogues with a Carboxyl Group at C-17 Isolated from the Bark ofScheffleraoctophylla. Journal of Organic Chemistry, 2000, 65, 6278-6282.	1.7	42
78	A Synthetic Triterpenoid, 2-Cyano-3,12-dioxooleana-1,9-dien-28-oic Acid (CDDO), Is a Ligand for the Peroxisome Proliferator-Activated Receptor Î³. Molecular Endocrinology, 2000, 14, 1550-1556.	3.7	151
79	Design and synthesis of 2-cyano-3,12-dioxoolean-1,9-dien-28-oic acid, a novel and highly active inhibitor of nitric oxide production in mouse macrophages. Bioorganic and Medicinal Chemistry Letters, 1998, 8, 2711-2714.	1.0	185
80	Design and Synthesis of 23,24-Dinoroleanolic Acid Derivatives, Novel Triterpenoidâ^'Steroid Hybrid Molecules. Journal of Organic Chemistry, 1998, 63, 4846-4849.	1.7	16
81	Partial Synthesis of Krukovines A and B, Triterpene Ketones Isolated from the Brazilian Medicinal PlantMaytenuskrukovii. Journal of Natural Products, 1997, 60, 1174-1177.	1.5	12
82	New enone derivatives of oleanolic acid and ursolic acid as inhibitors of nitric oxide production in mouse macrophages. Bioorganic and Medicinal Chemistry Letters, 1997, 7, 1623-1628.	1.0	82
83	Novel A-ring cleaved analogs of oleanolic and ursolic acids which affect growth regulation in NRP.152 prostate cells. Bioorganic and Medicinal Chemistry Letters, 1997, 7, 1769-1772.	1.0	32
84	Structure-activity relationship study on N-glycosyl moieties through model building of DNA and ellipticine N-glycoside complex. Bioorganic and Medicinal Chemistry Letters, 1996, 6, 1331-1334.	1.0	5
85	Synthesis and antitumor activity of quaternary ellipticine glycosides, a series of novel and highly active antitumor agents. Journal of Medicinal Chemistry, 1988, 31, 1295-1305.	2.9	28
86	Yandanziolide D, a new C19-quassinoid isolated from Brucea javanica (L.) MERR.. Chemical and Pharmaceutical Bulletin, 1988, 36, 841-844.	0.6	11
87	Stereoselective synthesis of 9-hydroxyellipticine glycosides, novel and highly active antitumor agents.. Chemical and Pharmaceutical Bulletin, 1987, 35, 3975-3978.	0.6	11
88	Preparation of a tricyclic A-ring analog of quassin.. Chemical and Pharmaceutical Bulletin, 1987, 35, 837-840.	0.6	7
89	Yadanzioside P, a new antileukemic quassinoid glycoside from Brucea javanica (L.) merr with the 3-O-(.BETA.-D-glucopyranosyl)bruceantin structure.. Chemical and Pharmaceutical Bulletin, 1986, 34, 4447-4450.	0.6	30
90	Structures of Yadanziosides K, M, N, and O, New Quassinoid Glycosides fromBrucea javanica(L.) MERR. Bulletin of the Chemical Society of Japan, 1986, 59, 3541-3546.	2.0	21

#	Article	IF	Citations
91	Two new quassinoid glycosides, yadanziosides N and O isolated from seeds of (L.) merr. Tetrahedron Letters, 1986, 27, 593-596.	0.7	17
92	Constituents of Seeds ofBrucea javanica. Structures of New Bitter Principles, Yadanziolides A, B, C, Yadanziosides F, I, J, and L.. Bulletin of the Chemical Society of Japan, 1985, 58, 2673-2679.	2.0	35
93	Structures of New Quassinoid Glycosides, Yadanziosides A, B, C, D, E, G, H, and New Quassinoids, Dehydrobrusatol and Dehydrobruceantinol fromBrucea javanica(L.) MERR. Bulletin of the Chemical Society of Japan, 1985, 58, 2680-2686.	2.0	39
94	Structures of yadanziolides A, B, and C, new bitter principles from Brucea javanica.. Chemical and Pharmaceutical Bulletin, 1984, 32, 4698-4701.	0.6	20
95	New quassinoid glycosides, yadanziosides A-H, from Brucea javanica.. Chemical and Pharmaceutical Bulletin, 1984, 32, 4702-4705.	0.6	21
96	SYNTHESIS OF (Â±)-3,3-ETHYLENEDIOXY-14Î±-HYDROXY-5-PICRASENE-11,16-DIONE, A 14Î±H-PICRASANE DERIVATIVE. Chemistry Letters, 1981, 10, 299-302.	0.7	8
97	A New Triterpene Glucoside fromTerminalia arjuna.Arjunglucoside III. Bulletin of the Chemical Society of Japan, 1979, 52, 3127-3128.	2.0	25
98	13Î±H-Olean-18-ene Derivatives. Forced Wolff-Kishner Reduction Products of 19-Oxoolean-12-ene Derivatives. Bulletin of the Chemical Society of Japan, 1978, 51, 884-888.	2.0	4
99	OLEAN-18-ENE DERIVATIVES WITH A 13Î±H-CONFIGURATION. Chemistry Letters, 1977, 6, 271-274.	0.7	0
100	Arjungenin, Arjunglucoside I, and Arjunglucoside II. A New Triterpene and New Triterpene Glucosides fromTerminalia arjuna. Bulletin of the Chemical Society of Japan, 1976, 49, 3213-3218.	2.0	57
101	The structure of arjungenin. A new sapogenin from Terminalia arjuna.. Chemical and Pharmaceutical Bulletin, 1976, 24, 178-180.	0.6	29